AstraZeneca Annual Report and Form 20-F Information 2016

Introduction to AstraZeneca

Watch our introduction to AstraZeneca's strategy and main therapy areas.

Financial highlights

Total Revenue*

down 7% to $23,002 million at actual rate of exchange (down 5% at CER)

* As detailed on page 142 of the downloadable PDF of the Annual Report, Total Revenue consists of Product Sales and Externalisation Revenue.

Net cash flow from operating activities

up 25% at actual rate of exchange to $4,145 million

2016 at a glance

A global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.

Our strategic priorities reflect how we are working to achieve our Purpose of pushing the boundaries of science to deliver life-changing medicines.

A science-led, innovation strategy

Distinctive R&D capabilities: small molecule and biologic medicine, including immunotherapies and protein engineering, as well as devices, biomarkers and translational science.

Broad R&D platform in three main therapy areas

Portfolio of specialty and primary care products

Global commercial presence, with strength in Emerging Markets

Commercial Highlights:
Growth Platforms grew by 4% (5% at CER) in 2016

  • Emerging Markets: Stable (growth of 6% at CER), supported by China, up 4% (10% at CER) to $2,636 million
  • Diabetes: Growth of 9% (11% at CER), as Farxiga/Forxiga became our largest-selling Diabetes medicine
  • Japan: Sales up 8% (decline of 3% at CER), reflecting exchange rate impact and a biennial price reduction
  • Brilinta/Brilique sales grew by 36% (39% at CER)
  • Respiratory: A decline of 5% (3% at CER), reflecting US pricing pressure for Symbicort
  • New Oncology: Strong sales with Tagrisso delivering sales of $423 million in its first full year

Our talented employees are committed to achieving our Purpose in a sustainable way and our Values foster a strong AstraZeneca culture

Research Centres

1) California, US  2) Gaithersburg, MD, US 3) Boston, MA, US  4) Gothenburg, Sweden
5) Shanghai, China  6) Osaka, Japan

59,700 Employees


of employees feel able to bring our Values to life in their daily work

Cambridge, UK (HQ)

Gothenburg, Sweden

Gaithersburg, Maryland US


Our capital-allocation priorities strike a balance between the interests of the business, our financial creditors and shareholders, and support our progressive dividend policy.

Distributions to shareholders $m 2016 2015 2014
Proceeds from issue of shares
(47) (43) (279)
Total 3,514 3,443 3,242

Dividend per Ordinary Share $          2016 2015 2014
Dividend per Ordinary Share
2.80 2.80 2.80

Dividend per Ordinary Share for 2016    $
Payment Date
First interim dividend 0.90
12 September 2016
Second interim dividend 1.90
20 March 2017
Total 2.80